Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 77

Sort by

Sort Order Select

Journal Articles

Higher CD56 Expression on Multiple Myeloma Cells Increases CD38 Expression, Reduces Intracellular NAD+ Levels, and Enhances the Efficacy of Daratumumab-Based Treatment Strategies

Giulia Giorgetti, Pamela Becherini, Elena Maroto-Martin, Daniela Fenoglio, Debora Soncini, Claudia Martinuzzi, Santina Bruzzone, Andrea Benzi, Aimable Nahimana, Chiara Rosa Maria Uras, Anaïs Schavgoulidze, Jessica Ng Fong, Roberto M. Lemoli, Nikhil C Munshi, Mariateresa Fulciniti, Michele Cea

Blood (2023) 142 (Supplement 1): 1951.

https://doi.org/10.1182/blood-2023-189439

Published: 2023

Journal Articles

Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Truly Refractory Hodgkin Lymphoma Patients Is Highly Effective and Responses Are Mediated By NK Cells

Blood (2023) 142 (Supplement 1): 2218.

https://doi.org/10.1182/blood-2023-189574

Published: 2023

Journal Articles

Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk AML

Blood (2023) 142 (Supplement 1): 1567.

https://doi.org/10.1182/blood-2023-189777

Published: 2023

Journal Articles

AML Treatment By the AXL Inhibitor Bemcentinib in Combination with Cytarabine Shows Clinical Efficacy Related to TNFα and Cytotoxic Immune Cells: A Single-Cell Translational Study from the BGBC003 Trial

Blood (2023) 142 (Supplement 1): 1540.

https://doi.org/10.1182/blood-2023-185499

Published: 2023

Journal Articles

The NAD + Metabolic Dependency Restriction Overcomes Drug-Resistance Phenotype of Multiple Myeloma CELLS

Debora Soncini, Pamela Becherini, Silvia Ravera, Claudia Martinuzzi, Alessio Nencioni, Santina Bruzzone, Francesco Piacente, Giulia Giorgetti, Francesco Ladisa, Michel A. Duchosal, Aimable Nahimana, Roberto M. Lemoli, Michele Cea

Blood (2023) 142 (Supplement 1): 6609.

https://doi.org/10.1182/blood-2023-189720

Published: 2023

Journal Articles

Bemcentinib (Oral AXL Inhibitor) in Combination with Low-Dose Cytarabine Is Well Tolerated and Efficacious in Older Relapsed AML Patients.Updates from the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results Indicating Bemcentinib Elicits Anti-AML Immune Responses

Blood (2021) 138 (Supplement 1): 3410.

https://doi.org/10.1182/blood-2021-147225

Published: 2021

Journal Articles

Prognostic Impact of Minimal Residual Disease Assessment in Elderly Patients with Secondary Acute Myeloid Leukemia. a Comparison between CPX-351 and Intensified Fludarabine-Based Regimens

Fabio Guolo, Paola Minetto, Marino Clavio, Maurizio Miglino, Riccardo Marcolin, Monica Passannante, Carola Riva, Michela Frello, Chiara Vernarecci, Elisabetta Tedone, Nicoletta Colombo, Enrico Carminati, Girolamo Pugliese, Clara Nurra, Antonia Cagnetta, Michele Cea, Marco Gobbi, Roberto M. Lemoli

Blood (2021) 138 (Supplement 1): 3442.

https://doi.org/10.1182/blood-2021-153060

Published: 2021

Journal Articles

Peripheral Blasts Are Associated with Response to Ruxolitinib and Outcome in Patients with Chronic-Phase Myelofibrosis

Blood (2021) 138 (Supplement 1): 3624.

https://doi.org/10.1182/blood-2021-152420

Published: 2021

Journal Articles

First Interim Analysis of the Italian Dante Study: De-Escalation before Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Treated with First-Line Nilotinib

Massimo Breccia, Elisabetta Abruzzese, Fabio Stagno, Alessandra Iurlo, Fabrozio Pene, Immacolata Attolica, Paolo Sportoletti, Patrizia Pregno, Sara Galimberti, Barbara Scappini, Roberto M. Lemoli, Sergio Siragusa, Isabella Capodanno, Francesca Chiodi, Giuseppe Nicola Saglio, Gianantonio Rosti

Blood (2021) 138 (Supplement 1): 1474.

https://doi.org/10.1182/blood-2021-145411

Published: 2021

Journal Articles

Differential Treatment Strategy in Polycythemia Vera Patients with Stable Suboptimal Response to Hydroxyurea: Clinical Correlations and Impact on Survival

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-140001

Published: 2020

Journal Articles

On-Demand Plerixafor with Cyclophosphamide and G-CSF for Hematopoietic Stem-Cell Mobilization in Multiple Myeloma Patients: Preliminary Results of a Prospective Observational Study (MOZOBL06877)

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-136316

Published: 2020

Journal Articles

Ruxolitinib Rechallenge in Resistant/Intolerant MF Patients: Frequency, Therapeutic Effects, and Impact on Outcome

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-139197

Published: 2020

Journal Articles

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with IDH 1/2 Mutations

Daniel A. Pollyea, Courtney D. Dinardo, MDMSc, Martha L. Arellano, MD, Arnaud Pigneux, MD PhD, Walter Fiedler, MD, Marina Konopleva, MD PhD, David A Rizzieri, MD, B. Douglas Smith, MD, Atsushi Shinagawa, MD PhD, Roberto M. Lemoli, Monique Dail, PhD, Yinghui Duan, PhD, Brenda J. Chyla, Jalaja Potluri, MD, Jean A Ridgeway, DNP, NP-C, Hagop M. Kantarjian, MD

Blood (2020) 136 (Supplement 1): 5–7.

https://doi.org/10.1182/blood-2020-134736

Published: 2020

Journal Articles

The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408)

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-136566

Published: 2020

Journal Articles

Pre-Transplant Minimal Residual Disease Evaluation Performed By Molecular WT1-Based or Multicolor Flow Cytometry Assessment Overcomes the Prognostic Value of Cytogenetic and Molecular Risk Factors at Diagnosis in Advanced Acute Myeloid Leukemia Patients

Fabio Guolo, MD, Paola Minetto, MD, Marino Clavio, MD, Nicoletta Colombo, PhD, Annalisa Kunkl, MD, Enrico Carminati, Carmen Di Grazia, MD, Anna Maria Raiola, MD, Filippo Ballerini, MD, Maurizio Miglino, PhD, Emanuele Angelucci, Roberto M Lemoli, MD, Marco Gobbi, MD

Blood (2017) 130 (Supplement 1): 3316.

https://doi.org/10.1182/blood.V130.Suppl_1.3316.3316

Published: 2017

Journal Articles

First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Blood (2017) 130 (Supplement 1): 99.

https://doi.org/10.1182/blood.V130.Suppl_1.99.99

Published: 2017

Journal Articles

Comparison of the Efficacy and Feasibility of R-CODOX-M/IVAC-R Versus Conventional R-CHOP As First Line Regimen for High Risk Diffuse Large B-Cell Lymphoma

Giulia Bartalucci, MD, Elisa Coviello, MD, Fabio Guolo, MD, Paola Minetto, MD, Massimiliano Gambella, Giulia Rivoli, MD, Daniela Guardo, MD, Filippo Ballerini, MD, Maurizio Miglino, PhD, Alberto Fabbri, MD, Roberto M Lemoli, MD, Monica Bocchia, Marco Gobbi, MD

Blood (2017) 130 (Supplement 1): 2851.

https://doi.org/10.1182/blood.V130.Suppl_1.2851.2851

Published: 2017

Journal Articles

CD38 Deregulation As Strategy to Make Multiple Myeloma Cells More Sensitive to NAD+ Depleting Agents

Michele Cea, MD, Antonia Cagnetta, MD, Debora Soncini, PhD, Paola Minetto, MD, Micaela Bergamaschi, MD, Giulia Rivoli, MD, Letizia Canepa, MD, Marco Gobbi, MD, Roberto M Lemoli, MD

Blood (2016) 128 (22): 5671.

https://doi.org/10.1182/blood.V128.22.5671.5671

Published: 2016

Journal Articles

Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis

Blood (2016) 128 (22): 1128.

https://doi.org/10.1182/blood.V128.22.1128.1128

Published: 2016

Journal Articles

Higher Versus Standard Doses of Recombinant Erythropoietin for the Treatment of Anemia in Patients with Myelodysplastic Syndromes: Results of a Retrospective Survey from the Italian Registry of Myelodisplastic Syndromes (FISM)

Blood (2016) 128 (22): 4342.

https://doi.org/10.1182/blood.V128.22.4342.4342

Published: 2016

NARROW

Higher CD56 Expression on Multiple Myeloma Cells Increases CD38 Expression, Reduces Intracellular NAD+ Levels, and Enhances the Efficacy of Daratumumab-Based Treatment Strategies

Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Truly Refractory Hodgkin Lymphoma Patients Is Highly Effective and Responses Are Mediated By NK Cells

Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk AML

AML Treatment By the AXL Inhibitor Bemcentinib in Combination with Cytarabine Shows Clinical Efficacy Related to TNFα and Cytotoxic Immune Cells: A Single-Cell Translational Study from the BGBC003 Trial

The NAD + Metabolic Dependency Restriction Overcomes Drug-Resistance Phenotype of Multiple Myeloma CELLS

Bemcentinib (Oral AXL Inhibitor) in Combination with Low-Dose Cytarabine Is Well Tolerated and Efficacious in Older Relapsed AML Patients.Updates from the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results Indicating Bemcentinib Elicits Anti-AML Immune Responses

Prognostic Impact of Minimal Residual Disease Assessment in Elderly Patients with Secondary Acute Myeloid Leukemia. a Comparison between CPX-351 and Intensified Fludarabine-Based Regimens

Peripheral Blasts Are Associated with Response to Ruxolitinib and Outcome in Patients with Chronic-Phase Myelofibrosis

First Interim Analysis of the Italian Dante Study: De-Escalation before Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Treated with First-Line Nilotinib

Differential Treatment Strategy in Polycythemia Vera Patients with Stable Suboptimal Response to Hydroxyurea: Clinical Correlations and Impact on Survival

On-Demand Plerixafor with Cyclophosphamide and G-CSF for Hematopoietic Stem-Cell Mobilization in Multiple Myeloma Patients: Preliminary Results of a Prospective Observational Study (MOZOBL06877)

Ruxolitinib Rechallenge in Resistant/Intolerant MF Patients: Frequency, Therapeutic Effects, and Impact on Outcome

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with IDH 1/2 Mutations

The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408)

Pre-Transplant Minimal Residual Disease Evaluation Performed By Molecular WT1-Based or Multicolor Flow Cytometry Assessment Overcomes the Prognostic Value of Cytogenetic and Molecular Risk Factors at Diagnosis in Advanced Acute Myeloid Leukemia Patients

First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Comparison of the Efficacy and Feasibility of R-CODOX-M/IVAC-R Versus Conventional R-CHOP As First Line Regimen for High Risk Diffuse Large B-Cell Lymphoma

CD38 Deregulation As Strategy to Make Multiple Myeloma Cells More Sensitive to NAD+ Depleting Agents

Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis

Higher Versus Standard Doses of Recombinant Erythropoietin for the Treatment of Anemia in Patients with Myelodysplastic Syndromes: Results of a Retrospective Survey from the Italian Registry of Myelodisplastic Syndromes (FISM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only